PRIORITY PARTNERS
7231 Parkway Dr., Suite 100
Hanover, MD 21076

JOHNS HOPKINS
HEALTH PLANS

Prior Authorization

JOHNS HOPKINS HEALTH PLANS (MEDICAID)

Enbrel - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at **1-410-424-4607**. Please contact Johns Hopkins Health Plans at **1-888-819-1043** with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Enbrel - Priority Partners MCO.

Drug Name (select from list of drugs shown)
ENBREL (etanercept)

Quantity Frequency Strength

Route of Administration Expected Length of Therapy

Patient Information
Patient Name: _____
Patient ID: _____
Patient Group No.: _____
Patient DOB: _____
Patient Phone:

Prescribing Physician
Physician Name: _____
Physician Phone: _____
Physician Fax: _____
Physician Address: _____
City, State, Zip: _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please circle the appropriate answer for each question.

1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? Y N

NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.

[If yes, skip to question 22.]

2. Does the patient have any of the following diagnoses: A) uveitis, B) sarcoidosis, C) graft-versus-host disease, D) interleukin-2 toxicity, E) Langerhan's cell histiocytosis, F) myositis, G) nephrotic syndrome, H) amyloidosis, I) periodic fever syndrome, J) renal transplant syndrome?	Y N	
[If yes, no further questions.]		
3. Does the patient have a diagnosis of moderately to severely active rheumatoid arthritis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 7.]		
4. Has the patient tried and had insufficient response to at least two formulary disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
5. Does the patient have a contraindication to at least two disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
6. Has the patient had rheumatoid arthritis for less than or equal to 6 months with high level of disease activity and features of poor prognosis (such as extra-articular disease, positive rheumatoid factor, or bony erosions)?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
[If no, no further questions.]		
7. Does the patient have a diagnosis of moderately to severely active juvenile idiopathic arthritis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 12.]		
8. Has the patient tried and had insufficient response to an adequate trial of full dose nonsteroidal anti-inflammatory drug (NSAID) therapy?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
9. Has the patient tried and had insufficient response to at least two formulary disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 11.]		
10. Does the patient have a contraindication to at least two disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	

NOTE: Submission of medical records is required.		
[If no, no further questions.]		
11. Is the patient 2 years of age or older?	Y N	
[If yes, skip to question 23.]		
[If no, no further questions.]		
12. Does the patient have a diagnosis of active psoriatic arthritis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 15.]		
13. Has the patient tried and had insufficient response to at least two formulary disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
14. Does the patient have a contraindication to at least two disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
[If no, no further questions.]		
15. Does the patient have a diagnosis of active ankylosing spondylitis?	Y N	
NOTE: Submission of medical records is required.		
[If no, skip to question 17.]		
16. Has the patient tried and had insufficient response to an adequate trial of two full doses nonsteroidal anti-inflammatory drug (NSAID) therapies?	Y N	
NOTE: Submission of medical records is required.		
[If yes, skip to question 21.]		
[If no, no further questions.]		
17. Does the patient have a diagnosis of chronic moderate to severe plaque psoriasis?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
18. Does the patient have either of the following: A) body surface area involvement of greater than 5 percent, or B) body surface area involvement of less than or equal to 5 percent, but involves sensitive areas (palms/soles of feet, genitalia and head/neck)?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		

19. Has the patient tried and had insufficient response to phototherapy or systemic disease-modifying antirheumatic drug (DMARD) therapy with methotrexate?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
20. Is the patient at least 4 years and less than or equal to 17 years of age?	Y N	
[If yes, skip to question 23.]		
21. Is the patient 18 years of age or older?	Y N	
[If yes, skip to question 23.]		
[If no, no further questions.]		
22. Is the patient experiencing clinical improvement from treatment supported by one of the following outcomes: A) reduction in the signs and symptoms, B) prolonged beneficial clinical response, C) inhibition of structural damage progression, or D) improved physical functioning?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
23. Is the requested drug being prescribed for FDA-approved dosages and dosing intervals?	Y N	
NOTE: Submission of medical records is required.		
[If no, no further questions.]		
24. Will the requested drug be used concurrently with another biologic disease-modifying anti-rheumatic drug (DMARD)?	Y N	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date